* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Alsace BioValley
Survey
Document related concepts
Discovery and development of integrase inhibitors wikipedia , lookup
DNA-encoded chemical library wikipedia , lookup
Drug interaction wikipedia , lookup
MTOR inhibitors wikipedia , lookup
Nicotinic agonist wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Discovery and development of neuraminidase inhibitors wikipedia , lookup
Metalloprotease inhibitor wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Discovery and development of antiandrogens wikipedia , lookup
Discovery and development of ACE inhibitors wikipedia , lookup
Transcript
Alsace BioValley CNS Oncology Immunology DELEGATE(S) Fabien Sebille, Project Manager Mona Boye 9 Bd Gonthier d'Andernach 67400 Illkirch France www.alsacebiovalley.com/fr/Homepage-186.html Incorporated: 1998 Employees: 18 Ownership: Private MISSION/BACKGROUND At Alsace Biovalley, we will represent a selection of innovative companies from our cluster: UROLEAD has developed a unique platform of in vivo screening models in onco-urology using FRESH tumours xenografted and maintained in nude mice (32 kidney, 6 bladder and 5 prostate cancer models). They can assess the anti-cancer efficiency of drug candidates with the possibility to identify predictive biomarkers associated to the treatment. More information at www.urolead.com. INNOVATIVE HEALTH DIAGNOSTICS (IHD) has developed innovative blood diagnostic for Alzheimer’s disease, making IHD one of the leader in the field. The technology is based on the detection of specific blood biomarkers (PKC and Abeta42 peptide) allowing a unique, non-invasive method of in vivo efficacy evaluation of candidates targeting the amyloid pathway. The tests are especially adapted for longitudinal studies, as very small blood samples are required. More information at www.ihdiag.com. TRANSGENE: fully integrated biopharmaceutical company that designs and develops cutting-edge immunotherapeutic products to treat cancers and chronic infectious diseases. They have particular interests in the following areas: Innovative vaccine technologies and anti-viral compounds (HCV, HBV, TB) Early stage therapeutic monoclonal antibodies for Cancer (HCC, colorectal, H&N…) or infectious diseases (HCV, HBV, TB) Immunomodulatory strategies to boost IL12 response www.transgene.fr RHENOVIA PHARMA is the leader of Biosimulation technologies in the CNS field and provides access to the first platform modeling a network of Glu/GABA synapses. This cutting edge technology can be applied to candidate profiling, side effects identification as well as screening of synergistic drug combinations leading to extended patent life. www.rhenovia.com TECHNOLOGY We will also present the latest out-licensing opportunities arising from academic research, gathered by CONECTUS, the unified Technology Transfer Office in Alsace (2 Universities, University Hospital, engineering schools, INSERM and CNRS labs): •New family of KIT/FLT3 kinases inhibitors with demonstrated in vivo efficacy and no signs of lung metastases commonly observed with SOC. •Dual HDAC/DNMT inhibitors •Peptidic antagonist of Neuropilin1 for angiogenesis inhibition •NCEs targeting CD13 (AP-N) for angiogenesis inhibition •Cardioprotective compounds against chemotherapies-induced toxicity •Beta2A receptor agonist for treatment of neuropathic pain •PPARa agonist for treatment of depression •DIS inhibitor against HIV1 (first in class) ALLIANCES Alsace BioValley is the french partner of BioValley, a leading trinational biocluster in Europe spreading over Alsace-France, South BadenGermany, and Basel area-Switzerland. Company Profiles – 8